ID: ALA5169821

Max Phase: Preclinical

Molecular Formula: C35H42N6O12

Molecular Weight: 738.75

Representations

Canonical SMILES:  O=C(CCCCCCNC(=O)c1ccc(NC(=O)COCCOCCNC(=O)COc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)cc1)NO

Standard InChI:  InChI=1S/C35H42N6O12/c42-27-14-13-25(33(47)39-27)41-34(48)24-6-5-7-26(31(24)35(41)49)53-21-29(44)36-16-17-51-18-19-52-20-30(45)38-23-11-9-22(10-12-23)32(46)37-15-4-2-1-3-8-28(43)40-50/h5-7,9-12,25,50H,1-4,8,13-21H2,(H,36,44)(H,37,46)(H,38,45)(H,40,43)(H,39,42,47)

Standard InChI Key:  PTJNYVXLFRBJGN-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 738.75

Molecular Weight (Monoisotopic): 738.2861

AlogP: 0.44

#Rotatable Bonds: 21

Polar Surface Area: 247.87

Molecular Species: NEUTRAL

HBA: 12

HBD: 6

#RO5 Violations: 3

HBA (Lipinski): 18

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 3

CX Acidic pKa: 8.91

CX Basic pKa:

CX LogP: -0.83

CX LogD: -0.84

Aromatic Rings: 2

Heavy Atoms: 53

QED Weighted: 0.04

Np Likeness Score: -0.89

References

1. He X, Hui Z, Xu L, Bai R, Gao Y, Wang Z, Xie T, Ye XY..  (2022)  Medicinal chemistry updates of novel HDACs inhibitors (2020 to present).,  227  [PMID:34775332] [10.1016/j.ejmech.2021.113946]

2. Sinatra L, Yang J, Schliehe-Diecks J, Dienstbier N, Vogt M, Gebing P, Bachmann LM, Sönnichsen M, Lenz T, Stühler K, Schöler A, Borkhardt A, Bhatia S, Hansen FK..  (2022)  Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity.,  65  (24.0): [PMID:36473103] [10.1021/acs.jmedchem.2c01659]

3. Li D, Yu D, Li Y, Yang R..  (2022)  A bibliometric analysis of PROTAC from 2001 to 2021.,  244  [PMID:36274273] [10.1016/j.ejmech.2022.114838]

Source

Source(1):

• Scientific Literature